Patents by Inventor John S. Markowitz

John S. Markowitz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140162896
    Abstract: The invention features compositions and methods that are useful for genotyping CES1 isoforms (CES1A1, CES1A2, CES1A3). The ability to specifically genotype one or more CES1 isoforms (e.g. CES1A1) is useful for assessing drug metabolism in a subject and guiding treatment selection.
    Type: Application
    Filed: April 19, 2012
    Publication date: June 12, 2014
    Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION
    Inventors: John S. Markowitz, Haojie Zhu
  • Publication number: 20120245201
    Abstract: The present invention relates to the identification of isopropylphenidate as a useful therapeutic agent in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) as well as various fatigue causing disease and disorders and medication induced fatigue.
    Type: Application
    Filed: July 21, 2010
    Publication date: September 27, 2012
    Inventors: John S. Markowitz, Kennerly S. Patrick, Haojie Zhu
  • Publication number: 20110020801
    Abstract: Methods and kits are provided for detecting polymorphisms in carboxylesterase-1 (CES1). Several single nucleotide polymorphisms (SNPs) in CES1 in humans, and methods for detecting the same, are provided (e.g., Gly143Glu, 12754T>del). Results indicate that the Gly143Glu (9486G>A) polymorphism has an allelic frequency of 1.5% in the Caucasian population. Polymorphisms of the present invention may alter the function of the carboxylesterase-1 enzyme (hCES1). Thus, the methods and kits of the present invention may be used to personalize a therapy and/or avoid adverse consequences of altered metabolism of a therapeutic or compound (e.g., enalapril, methylphenidate, etc.) which may result due to a CES1 polymorphism. In addition, recombinant cells lines overexpressing wild-type CES1 or expressing CES1 mutants are provided. Such cell lines may be used to assess the effects of candidate compounds on CES1, and the action of CES1 on these candidate compounds.
    Type: Application
    Filed: June 9, 2008
    Publication date: January 27, 2011
    Inventors: John S. Markowitz, Haojie Zhu
  • Patent number: 6245360
    Abstract: A single entity product is provided for administration to persons being treated for nutritional deficiencies associated with addiction to alcohol, wherein the product is an extended-release multivitamin with minerals and trace elements in beneficial dose ranges and specifically contains thiamine and folic acid in the desired amounts of about 100 mg and 1 mg, respectively. The product may also contain riboflavin in an amount between about 1 mg and about 3 mg, pyridoxine in an amount between about 1 mg and about 3 mg, cyanocobalamin in an amount between about 6 mg and about 12 mg, biotin in an amount between about 10 mcg and about 50 mcg, niacin in an amount between about 10 mg and about 50 mg, vitamin D in an amount between about 200 IU and about 500 IU, vitamin E in an amount between about 10 IU and about 50 IU, selenium in an amount between about 5 mcg and about 50 mcg, and/or magnesium in an amount between about 100 mg and about 400 mg.
    Type: Grant
    Filed: June 25, 1999
    Date of Patent: June 12, 2001
    Inventor: John S. Markowitz